These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. New heparin is no heavyweight. Feinberg AW Health News; 2000 Aug; 6(8):5-6. PubMed ID: 10948870 [No Abstract] [Full Text] [Related]
6. Low-molecular-weight heparin for initial treatment of venous thromboembolism. Brewer D Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683 [No Abstract] [Full Text] [Related]
7. Current and potential uses of low molecular weight heparin: a review and an economic analysis. Seo P; Locke CF Am J Manag Care; 2000 Apr; 6(4):498-506; quiz 507-8. PubMed ID: 10977456 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism. Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253 [TBL] [Abstract][Full Text] [Related]
10. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States. Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278 [TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Holzheimer RG Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403 [TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin in treatment of venous thromboembolism. An emerging theme. Hull RD; Pineo GF Int Angiol; 1998 Sep; 17(3):131-4. PubMed ID: 9821024 [No Abstract] [Full Text] [Related]
13. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV; N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276 [TBL] [Abstract][Full Text] [Related]
14. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296 [TBL] [Abstract][Full Text] [Related]
15. Low-molecular weight heparin as prophylaxis against thromboembolism after total hip replacement--is it worth the price? Persson BM Acta Orthop Scand; 2000 Apr; 71(2):215-6. PubMed ID: 10852334 [No Abstract] [Full Text] [Related]
16. [Low molecular weight heparins: mechanisms of action and pharmococynetics. Clinical advantages over the classic unfractioned heparins]. Campos M Rev Port Cir Cardiotorac Vasc; 2003; 10(2):61-7. PubMed ID: 15094887 [TBL] [Abstract][Full Text] [Related]
17. [State of the art: low-molecular-weight heparin and beyond]. Cimminiello C; Casali G; Vitali L Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343 [TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin prophylaxis against thromboembolism after total hip replacement--the never-ending story? Dahl OE; Bergqvist D; Cohen AT; Frostick SP; Hull RD Acta Orthop Scand; 2001 Apr; 72(2):199-204. PubMed ID: 11372955 [No Abstract] [Full Text] [Related]